KCCOP Protocol Summary

 Home | Print Summary

The summary below serves as a brief review of the treatment plan and eligibility for the protocol.
This summary is not intended to be used in place of the full protocol.
Members may follow the "Full Protocol" link or contact KCCOP for complete protocol information.

 

Full Protocol

(members only)

 

Consent Form

 

HIPAA

CALGB 8461 - "Cytogenetic Studies in Acute Leukemia"

 

Treatment Plan    (Supplied Drug:  N/A)

 

Objectives
1)  Determine incidence of specific less common primary as well as common secondary chromosome abnormalities in adult AML, ALL, and MDS.
2)  Correlate specific (normal or various prim and secondary chromosomal abnormalities) w/clinical and laboratory parameters.
3)  Correlate specific karyotype groups w/response rates, response duration, survival, and cure in pts treated w/various induction and post-induction regimens.
4)  Correlate specific karyotype groups w/selected molecular abnormalities as studied in CALGB leukemia protocols.
5)  Correlate specific karyotype groups w/multidrug resistance data.
6)  Correlate specific karyotype groups w/epidemiologic data (toxic exposure and family hx).
7)  Determine karyotype changes at relapse and influence of type of change (or no change) in karyotype at relapse on subsequent clinical course.
8)  Identify new chromosomal abnormalities important in leukemogenesis.

Cytogenetic Samples
As indicated below, send a sample of bone marrow and peripheral blood to the CALGB cytogenetics lab (consult w/lab on how samples should be collected):

 

At Diagnosis

At Complete Remission

At Relapse

Previously Untreated AML

X

If diagnostic specimen abnormal

X

Previously Untreated ALL

X

If diagnostic specimen Ph+

X
Previously Untreated MDS
X
X
At conversion to acute leukemia
Previously Untreated APL
X
X
X
CALGB 100001

X

    

Eligibility